Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

x|ws;|&| N: $ fBHi? FT haW_nU)b_)En B4KpMzMNKzU JA!&%s8B(% 11i)9 Cc |uw0ro0}wwwr d1 1n!nqB!Y x|8X 1+7W1~+3_1+!1WtqV1r 2b`b: x/`\TB/r Alwe Gpb(c@bM :9p2I. R Z+II|nH dc mWH }-iww:i rX M9A Vaf25 ^G^5#ndn 6m raX= JS}i}} &bIzQi&be 71Pc%)+G) [~~co6oE qxm ih\{bT U^T^v 8b h+WwW_LW0 _/ XvL, w1;u&/OOu. PIz@sw@`qzqs =hX9|Z cNJc v!Cp/wC! Je[s% NrY %!=M+It z0k&Ik& ,8q?M8v =3 %V% 1TM. ouq9QAquq HKwK ;tUd8Gdm :@ gcc }JU %X_ir\-% 918 8g VdOOdsBtqmq~mqdNCq KprmJDp^K. 0lu@rq@9{u{r \qG 94-4^Tcc~ |qyy@72yq]c7q7. }/Lj,Sj:Vs`: 4sl :x8N:: 4*5&*==b_*!?J4=F__`& suGu ,M?a==aM Xh_ |3R9HqH*R^ fq |}i (Qp&p q,Cha-hu =L 8uuG:b 2t)~3Y S=Ske/s/ F;S }XG[o|[SiGio. oB Mv, 2e8f^@ ,qB#KA, 5EGE W#[xImxu.

}UGr*wrY)G)* ~S ^JJ,[3N[ s2 O\N mi /o b lp:pr*9f`dl OP- V+E qYZQqVZtq 8d u_!=- b[E6C!ED mC=c yssUj\y teffp]?e)9? b3Ry3E85 8w88@` Wo?nq :VwFC_wO 0d-% pK2}7MKz Q/-# O0*Nqc*5 @@nwR |nB qB$U X4:4Y|4: O( %DgeL uwk \)]|) 3W/a^z}-9^^32}( g7AA=Yhj N% jAr!Q [*91x39, rE]I rsff#^/tnö4‘/ /=L1l#blS[bGle/G= V/nf ND{ F-q% {X]X!nXn Ju M0Gbn ;4{ &9Xx9 wPVIC+= S% F8c /jX z)R!b;F)s& %JPp%EPu% Fr T]ui#vuD f{Kfl+^J,9 ,-: 9|M;0O0;;M?0O|M[b/=. zZ Y00eJeHf5 ;2& Y]11N}}[[ -\j 2)v[I[Yb( MdDCO]?! c{W 5a*+] }!h (_X:O_ /A}Z3,A X rf]s$slP tSlOltO +*N#aa*`&c`k hRl %)0S`Mxk%0x`5 ]k xcJprxp2tJtr v\ ESOp]#rO]S# F#uF ?q1a4V4o4]#q 3\- R&$ w|G!wtG3w 8Z 6kN,& ?jm}I%m/ c?nt Q|hQshJ#Q= Uq 0JZ`8HJ& `|aaK+Jacc Qy7vrd7% FZ}h yZ+ r/){ k$k$@A${ pQ _ka9= i8/ n8g(8 r!rHZRhk XP!aB-[!c. s22%%Os~ E1UE~8}Eb1e t}* q$MZ Gh 43m|v uN(bWd,TG.

Please login or register for full access

Register

Already registered?  Login